{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:44:38Z","timestamp":1776062678309,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze the relationship between tumor regression patterns and ypN positivity and explore their implications for postoperative nodal-risk stratification after neoadjuvant or conversion therapy in advanced gastric cancer, while generating hypotheses for future individualized lymphadenectomy research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tumor regression patterns were classified as centripetal, diffuse\/mixed, or centrifugal. Clinical and pathological characteristics were compared using the Kruskal\u2013Wallis and \u03c7\u00b2 tests. Using ypN positivity as the outcome, a multivariable logistic regression model was constructed. Sensitivity analyses were performed in the subgroup with \u226516 retrieved lymph nodes, after additional adjustment for ypT and Becker tumor regression grade (TRG), and in the non-pCR subgroup. Internal validation was performed using a 7:3 stratified random split and 10-fold cross-validation. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), 95% confidence intervals, calibration, and the Brier score. We additionally compared a baseline clinicopathological model with a combined model incorporating regression pattern to assess incremental predictive value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 195 patients, 74 (38.0%) exhibited centripetal regression, 43 (22.1%) had diffuse\/mixed regression, and 78 (40.0%) demonstrated centrifugal regression. Centripetal regression was characterized by low PRI, higher LRI and CER, and a very low ypN positivity rate (5.4%), whereas centrifugal regression showed the opposite pattern and the highest ypN positivity rate (75.6%); diffuse\/mixed regression showed intermediate features (all p &amp;lt; 0.001). Multivariable analysis identified diffuse\/mixed and centrifugal regression as the strongest independent predictors of ypN positivity. The apparent full-cohort model demonstrated an AUC of 0.875 (95% CI 0.826\u20130.922) with good calibration and a Brier score of 0.137. These associations remained robust after additional adjustment for ypT and Becker TRG and in the non-pCR subgroup. Internal validation showed acceptable performance, with a validation AUC of 0.826 in the 7:3 split-sample analysis and a pooled AUC of 0.822 in 10-fold cross-validation. Addition of regression pattern to the baseline clinicopathological model improved discrimination and reduced prediction error.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pathological regression patterns provide effective stratification of residual lymph node metastasis after neoadjuvant or conversion therapy. Centripetal regression indicates a very low residual nodal-risk phenotype, whereas centrifugal regression is associated with a heavier nodal burden. At present, regression patterns may be most appropriately used for postoperative risk assessment and multidisciplinary stratification. Their potential role in individualized lymphadenectomy should be viewed as a future translational direction requiring validated preoperative or intraoperative surrogate markers and prospective confirmation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1766242","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:46:01Z","timestamp":1776059161000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From centripetal to centrifugal: pathological regression patterns after neoadjuvant or conversion therapy as markers of nodal risk and a framework for future research on individualized lymphadenectomy in gastric cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Na","family":"Li","sequence":"first","affiliation":[{"name":"Lanzhou University Second Clinical Medical College","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penghui","family":"Liu","sequence":"additional","affiliation":[{"name":"Lanzhou University Second Clinical Medical College","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwu","family":"Guo","sequence":"additional","affiliation":[{"name":"Lanzhou University Second Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jizhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Lanzhou University Second Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gengyutong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Northeastern University","place":["Boston, MA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyuan","family":"Mou","sequence":"additional","affiliation":[{"name":"Lanzhou University Second Clinical Medical College","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Mao","sequence":"additional","affiliation":[{"name":"Lanzhou University Second Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","year":"2023","journal-title":"Gastric Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.252","article-title":"Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer","volume":"115","author":"Martin-Romano","year":"2016","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12957-022-02725-9","article-title":"Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy","volume":"20","author":"Jiang","year":"2022","journal-title":"World J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6597","article-title":"Tumor regression grade combined with post-therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma","volume":"12","author":"Yin","year":"2023","journal-title":"Cancer Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijsu.2018.08.002","article-title":"Integrated analysis of the prognostic role of the lymph node ratio in node-positive gastric cancer: A meta-analysis","volume":"57","author":"Zhu","year":"2018","journal-title":"Int J Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i21.107029","article-title":"Evaluating log odds of positive lymph nodes as a prognostic tool in differentiated gastric cancer: A retrospective study","volume":"31","author":"Deng","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26391","article-title":"Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single-center experience","volume":"123","author":"Lombardi","year":"2021","journal-title":"J Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10120-020-01098-w","article-title":"Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A","volume":"24","author":"Fujitani","year":"2021","journal-title":"Gastric Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12957-023-03291-4","article-title":"Development and evaluation of the Newstage system: integrating tumor regression grade and lymph node status for improved prognostication in neoadjuvant treatment of gastric cancer","volume":"22","author":"Chen","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/jso.25785","article-title":"Lymph node regression after neoadjuvant chemotherapy: A predictor of survival in gastric cancer","volume":"121","author":"Pereira","year":"2020","journal-title":"J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2025.0410","article-title":"Neoadjuvant therapy for mucosal head and neck squamous cell carcinoma: A review from the American Head and Neck Society","volume":"151","author":"Contrera","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071302","article-title":"An updated review of management of resectable stage III NSCLC in the era of neoadjuvant immunotherapy","volume":"16","author":"Verma","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.982011","article-title":"The modified shrinkage classification modes could help to guide breast conserving surgery after neoadjuvant therapy in breast cancer","volume":"12","author":"Bi","year":"2022","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-22-477","article-title":"Rectal tumor fragmentation as a response pattern following chemoradiation","volume":"13","author":"Mills","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003129","article-title":"The pattern of residual tumor after neoadjuvant chemotherapy for locally advanced esophageal cancer and its clinical significance","volume":"271","author":"Hashimoto","year":"2020","journal-title":"Ann Surg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"18278","DOI":"10.1038\/s41598-020-74067-z","article-title":"Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems","volume":"10","author":"Matsuda","year":"2020","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.03.227","article-title":"Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer","volume":"41","author":"Biondi","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189350","article-title":"Tumor immune microenvironment remodeling after neoadjuvant therapy in gastric cancer: Update and new challenges","volume":"1880","author":"Sun","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12957-024-03388-4","article-title":"Optimal lymph node dissection for gastric cancer: a narrative review","volume":"22","author":"Nico","year":"2024","journal-title":"World J Surg Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1766242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:46:01Z","timestamp":1776059161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1766242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1766242"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1766242","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1766242"}}